Zontivity (vorapaxar)
Additional monitoring
- Region
- 🇪🇺 EU
- Active substance
- vorapaxar
- Company
- Merck Sharp Dohme Limited
- Status
- Withdrawn
- Therapeutic area
- Myocardial Infarction
- EU approval
- Mon 19 Jan 2015
- Designations
- Additional monitoring
- Application
- EMEA/H/C/002814
- ATC
- B01
- Official record
- www.ema.europa.eu
Indication
Zontivityis indicated for the reduction of atherothrombotic events in adult patients with a history of myocardial infarction (MI), ,co-administered with acetylsalicylic acid (ASA) and, where appropriate, clopidogrel; or symptomatic peripheral arterial disease (PAD), co-administered with acetylsalicylic acid (ASA) or, where appropriate, clopidogrel.
Regulatory milestones
No milestones recorded in the last year.
Follow Zontivity
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.